Patient Radiation Alarms After Nuclear Medicine

Q: What is NRC Regulatory Guide 8.39?

Regulatory Guide 8.39, 'Release of Patients Administered Radioactive Material,' is the NRC guidance that describes how licensees determine whether a patient can be released after receiving radioactive material and what instructions to provide. Revision 1, issued in 2020, is the current version. It advises informing patients that they may trigger radiation detectors and suggests issuing documentation when appropriate.

A patient can walk out of a nuclear medicine department cleared for release and still set off a radiation detector at an airport three weeks later. Security radiation portal monitors and handheld detectors are built to sense the tiny quantities of radioactive material that matter for interdiction — quantities thousands of times smaller than a routine therapeutic dose — so a recently treated patient becomes, from the detector's point of view, an unmistakable source. NRC Regulatory Guide 8.39 anticipates exactly this, and expects licensees to warn patients and, where appropriate, hand them documentation. ^{1, 4}

This article explains the physics behind why patients trigger these alarms, how long the effect lasts for common radiopharmaceuticals, what the regulations require at patient release, and how a nuclear medicine program should build patient instructions and wallet cards into its radiation safety program. DRPS supports this through its radiation safety officer consulting and PET/CT and nuclear medicine physics services.

Introduction

Since the mid-2000s, the deployment of radiation detection equipment for homeland security has quietly reshaped a corner of nuclear medicine practice. Radiation portal monitors now stand at borders, seaports, and many airports; handheld and pager-style detectors are carried by security and law-enforcement personnel; and fixed monitors guard the entrances of some government and financial buildings. All of them are tuned to catch small, illicit sources of radioactive material — and all of them will happily register a patient who received a radiopharmaceutical days or weeks earlier. ⁴

This is not a hypothetical inconvenience. A patient stopped by security, questioned, and possibly detained because a detector alarmed — with no explanation of why — is a genuine problem for the patient and a foreseeable one for the licensee. The NRC addressed it directly: Regulatory Guide 8.39 advises that patients be told they may trigger such detectors and that licensees consider providing a card or letter documenting the treatment. ¹ Building that into the release workflow is both good patient care and good radiation safety program design.

The topic sits at the intersection of patient release regulation, radiation physics, and practical clinic operations — squarely in the domain of the radiation safety officer (RSO) and the medical physicist. It connects directly to our companion post on patient release after radiopharmaceutical therapy.

Topic Explanation

Detection is not the same as hazard

The single most important concept to keep straight is that triggering a detector is a measurement event, not a hazard threshold. Patient release in the United States is governed by dose, not detectability. Under 10 CFR 35.75, a licensee may release a patient containing radioactive material if the total effective dose equivalent to any other individual is not likely to exceed 5 mSv (0.5 rem). ² A patient who satisfies that limit — and is therefore lawfully and safely released — can still carry more than enough activity to be detected by security equipment far more sensitive than the release criterion contemplates.

In other words: the release decision protects the public from dose; the detector responds to presence. The gap between those two thresholds is exactly why released, safe patients set off alarms. ^{1, 2}

Why security detectors are so sensitive

Radiation portal monitors are designed around the security mission: detect small quantities of radioactive or nuclear material that someone might attempt to move covertly. That drives their sensitivity floor far below anything medically relevant. As Dauer and colleagues noted, the activity levels of many medical radionuclides are on the order of a thousand to more than ten thousand times the levels these pedestrian systems are designed to detect — so a medical patient can drive a portal's count rate above its alarm threshold while still several meters away from the monitor. ⁴

The scintillator materials in these systems (large plastic or sodium iodide detectors) are also efficient at the photon energies medical isotopes emit — the 140 keV of Tc-99m, the 159 keV of I-123, the 364 keV of I-131, the 511 keV annihilation photons of PET tracers — which further guarantees a strong response.

How long the effect lasts: the physics

Two quantities set how long a patient remains detectable: the administered activity and the effective half-life (the combination of physical decay and biological clearance). Physical decay alone follows:

A (t) = A_{0} e^{- λ t}, λ = \frac{ln 2}{T _{1/2}}

where $A_{0}$ is the retained activity, $λ$ is the decay constant, and $T_{1/2}$ is the half-life. A patient continues to trip a detector until the retained activity falls below that detector's effective sensitivity, $A_{m i n}$ . Solving for the time:

t_{detectable} = \frac{T _{1/2}}{ln 2} ln (\frac{A _{0}}{A _{m i n}})

A worked example. Consider an I-131 thyroid cancer ablation of $A_{0} = 5.55$ GBq (150 mCi), with $T_{1/2} = 8.02$ days for I-131. Suppose — purely as an illustration — that a sensitive portal effectively responds down to $A_{m i n} \approx 1$ MBq of retained activity in the patient. Then:

t_{detectable} = \frac{8.02}{ln 2} ln (\frac{5.55 \times 1 0 ^{9}}{1 \times 1 0 ^{6}}) = 11.6 \times ln (5550) \approx 11.6 \times 8.62 \approx 100 days

The exact figure depends heavily on the assumed detector sensitivity, on biological clearance (which shortens the real timeline versus physical decay alone), and on shielding by the patient's own tissue — so this is a physics illustration, not a promise. But the order of magnitude is right, and it matches the NRC's own qualitative statement that I-131 therapy patients may trigger detectors for several weeks to months. ¹ The lesson is that half-life dominates: a short-lived tracer clears in days, while I-131 keeps a patient detectable for a remarkably long time.

Key Technical Principles

Detectability by radiopharmaceutical

The following table combines physical half-lives (from standardized decay data) with the detectability timelines reported in the literature and NRC guidance. Detectability is approximate because it depends on administered activity, biological clearance, and the specific detector.

Radiopharmaceutical	Physical half-life	Principal photon	Typical use	Approx. time detectable by sensitive security equipment
Tc-99m	6.0 h	140 keV	Bone, cardiac, renal, SPECT	Up to about 6 days ⁴
F-18 (FDG)	110 min	511 keV	PET oncology, cardiac, brain	Roughly 1 day (short half-life)
Ga-68	68 min	511 keV	PSMA, DOTATATE PET	Under a day (very short half-life)
I-123	13.2 h	159 keV	Thyroid uptake, DaTscan	A few days
Tl-201	73 h (3.0 d)	69–80 keV x-rays	Myocardial perfusion	Up to ~33 days (pager), ~51 days (portal) ⁴
In-111	2.8 d	171, 245 keV	WBC, OctreoScan	Roughly 1–2 weeks
I-131	8.0 d	364 keV	Thyroid therapy, some diagnostics	Several weeks to months ¹
Lu-177	6.65 d	113, 208 keV	PRRT, PSMA therapy	Weeks
Ra-223	11.4 d	82–270 keV	Bone-metastatic prostate cancer	Weeks (low photon yield)

Two entries carry firm, published numbers: Dauer and colleagues estimated that a Tl-201 cardiac patient may trigger pager-style detectors for up to 33 days and portal detectors for up to 51 days, versus up to about 6 days for Tc-99m myocardial studies. ⁴ The I-131 "weeks to months" figure is the NRC's own characterization. ¹ The remaining entries are physics-based estimates that scale with half-life and administered activity, and should be treated as guidance rather than guarantees.

The distance dimension

Because portals respond at a distance, the inverse-square law matters. The photon fluence rate — and thus the detector's count rate — falls with the square of the distance $d$ between patient and monitor:

\dot{C} (d) \propto \frac{A}{d ^{2}}

This is why a patient can alarm a portal several meters out: the activity is so far above the detection floor that even the reduced fluence at distance clears the threshold. It also explains a practical mitigation — a patient who is, unavoidably, still somewhat "hot" and must pass near a monitor will produce a smaller signal the farther they stay from it, though this is rarely something the patient can control at a security checkpoint. ⁴

Effective half-life shortens the real timeline

Physical decay is the upper bound. In reality, biological excretion removes activity too, so the effective half-life is shorter:

\frac{1}{T _{eff}} = \frac{1}{T _{phys}} + \frac{1}{T _{biol}}

For freely cleared tracers, biological washout dominates the first day or two, which is why the practical detectable time is often shorter than a physical-decay-only calculation suggests — except for agents like I-131 in functioning thyroid tissue, where biological retention is long and physical decay governs. This is the same effective-half-life framework used in patient release calculations. ^{3, 5}

Clinical Impact

The patient experience

For the patient, an unexplained security stop is stressful and occasionally serious — missed flights, secondary screening, questioning, and in rare cases detention while officials verify the source. A patient who was warned, and who carries a card, resolves the encounter in seconds by handing over documentation. A patient who was not warned may not even connect the alarm to their recent scan. The difference in experience is entirely a function of what the licensee did at release. ^{1, 4}

The program's exposure

For the licensee, failing to warn patients is a gap an inspector can find and a patient can complain about. NRC guidance frames patient instructions as part of the release process, and a program that documents "released patient; provided verbal and written instructions including detector-alarm advisory; issued wallet card" has closed the loop. It is a low-cost, high-value element of the radiation safety program that also demonstrates the kind of patient-centered practice accreditors look for. ^{1, 2}

Where it fits in the therapy workflow

For radionuclide therapies — I-131 for thyroid disease, Lu-177 PRRT and PSMA therapy, Ra-223 — the detector-alarm advisory belongs in the same conversation as the release instructions about contact time, sleeping arrangements, and travel. Travel is often explicitly restricted or advised against for a period after high-activity I-131 therapy, precisely because of both dose-to-others and detector considerations. The written directive and release record are the natural home for documenting that the advisory was given. See our related coverage of written directives in nuclear medicine. ^{1, 6}

Practical Optimization Tips

1. Make the alarm advisory a standard release element

Bake it into the release instruction template for every procedure above a set activity threshold, not just therapies. A Tl-201 cardiac patient can be detectable for weeks and is easy to overlook. ⁴

2. Issue a wallet card for therapies and high-activity studies

The card should state the radionuclide, the administered activity or a general description, the date of administration, the expected period of potential detectability, and a 24-hour facility contact number. NRC guidance specifically suggests the licensee consider issuing such documentation. ¹

3. Match the message to the isotope

Tell the I-131 therapy patient "weeks to months"; tell the Tc-99m scan patient "a few days." A generic message either over-alarms the short-lived-tracer patient or under-prepares the therapy patient. Use the half-life to calibrate the advice. ^{1, 4}

4. Cover travel explicitly for therapy patients

Advise therapy patients when it is reasonable to resume air travel and cross-border trips, and remind them to carry the card. For international travel after I-131, detectability can outlast the trip planning window. ¹

5. Document that the advisory was given

Record the verbal and written instruction and the card issuance in the patient's release record. Documentation is what turns a good practice into a defensible one at inspection. ^{1, 2}

6. Train the front-line staff

The technologists and nurses who discharge patients should be able to explain the advisory in plain language and answer the "will I be radioactive?" question accurately. This is a standard element to fold into the annual radiation safety training program.

Regulatory Considerations

Patient release and the associated instructions are governed by NRC regulation and guidance, administered by the NRC or the Agreement State. The framework is well defined:

10 CFR 35.75 — Release of individuals containing unsealed byproduct material. Authorizes release when the projected total effective dose equivalent to any other individual is not likely to exceed 5 mSv, and requires that instructions be provided when the dose to another individual could exceed 1 mSv. ²
NRC Regulatory Guide 8.39, Revision 1 (2020) — Release of Patients Administered Radioactive Material. The current guidance on release calculations and patient instructions, including the advisory that patients may trigger radiation detectors and the recommendation to consider issuing documentation. (A Revision 2 has been in draft; Revision 1 remains the effective guidance.) ¹
10 CFR Part 20 — Standards for Protection Against Radiation. The dose-limit framework underlying the public-dose basis for release. ³
NRC NUREG-1556, Volume 9 — medical-use licensing guidance, which frames the RSO's responsibilities for patient release and instructions within the license. ⁷

Agreement States administer their own equivalent programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license and inspect medical use of radioactive material under their own regulations, while Washington, DC and Delaware are regulated directly by the NRC. The release dose criterion and the expectation to provide instructions are consistent across these programs, but each licensee should confirm its specific state requirements. International guidance — ICRP Publication 94, IAEA Safety Reports Series No. 63, and NCRP Report No. 155 — provides the broader consensus basis for release and post-therapy patient management, including the detector-alarm phenomenon. ^{1, 2, 5, 6, 7}

DRPS helps facilities translate these requirements into working release procedures, instruction templates, and wallet cards through its radiation safety officer consulting and radioactive material license support.

Frequently Asked Questions (FAQs)

Can a nuclear medicine patient set off airport radiation detectors?

Yes. Security radiation portal monitors and handheld detectors are designed to sense very small amounts of radioactive material, so a patient carrying the activity from a recent nuclear medicine scan or therapy can trigger them. Depending on the radiopharmaceutical, this can happen from a few meters away and continue for days, weeks, or even months after the procedure.

How long will I be radioactive after a nuclear medicine test?

It depends on the radiopharmaceutical and the amount given. After a routine Tc-99m scan a patient may trigger sensitive detectors for a few days; after a Tl-201 cardiac study, potentially several weeks; and after I-131 therapy, NRC guidance notes that patients may set off detectors for several weeks to months. The physical half-life and the administered activity together set the timeline.

What is NRC Regulatory Guide 8.39?

Regulatory Guide 8.39, "Release of Patients Administered Radioactive Material," is the NRC guidance that describes how licensees determine whether a patient can be released after receiving radioactive material and what instructions to provide. Revision 1, issued in 2020, is the current version. It advises informing patients that they may trigger radiation detectors and suggests issuing documentation when appropriate.

Should patients get a card after radioactive treatment?

For therapies and higher-activity procedures, yes. NRC guidance recommends that licensees consider giving the patient a letter or wallet card stating the radionuclide, the administration date, and contact information for the facility, so that security officials can verify the source is medical. Many nuclear medicine programs issue such cards as routine practice.

Why are security detectors so sensitive to medical isotopes?

Radiation portal monitors are engineered to detect the small quantities of radioactive material relevant to security threats. The activities used in nuclear medicine are often thousands of times larger than what those systems are designed to detect, so a patient can register on a detector while still well away from it — sometimes at a distance of several meters.

Is it dangerous to others if a patient triggers an alarm?

Triggering a detector is a detection event, not a measure of hazard. Patients are only released when the projected dose to others meets the regulatory limit — in the United States, that no other individual is likely to receive more than 5 mSv. An alarm means the equipment sensed radioactivity, not that the patient poses a radiation risk to the public.

Key Takeaways

Detection is not hazard. Patient release is governed by a 5 mSv dose criterion to others, while security detectors respond to mere presence — so lawfully released, safe patients can still alarm. ^{2, 4}
Security detectors are extraordinarily sensitive. Medical activities can exceed their detection floor by a thousandfold or more, so patients can trigger portals from several meters away. ⁴
Half-life sets the timeline. Tc-99m patients may be detectable for days, Tl-201 patients for weeks (up to ~33 days on pagers, ~51 days on portals), and I-131 therapy patients for weeks to months. ^{1, 4}
NRC Reg Guide 8.39 Rev 1 is the anchor. It advises informing patients of the alarm possibility and recommends issuing a card or letter. ¹
A wallet card resolves the problem in seconds. It should name the radionuclide, the administration date, and a facility contact. ¹
Document the advisory. Recording that verbal and written instructions, including the detector advisory, were given closes the loop at inspection. ^{1, 2}

Conclusion

The spread of homeland-security radiation detection turned a physics footnote into a routine patient-care issue: people who are perfectly safe to be around can nonetheless light up a portal monitor for days, weeks, or months. The regulatory response is measured and practical — tell patients it can happen, calibrate the message to the isotope, and give therapy patients documentation they can produce at a checkpoint.

For the RSO and medical physicist, this is one of the easiest high-value additions to a radiation safety program: a line in the release template, a stack of wallet cards, and a trained discharge staff. It protects patients from an avoidable ordeal, protects the licensee from an avoidable finding, and reflects the kind of anticipatory, patient-centered practice that defines a mature program.

How DRPS Can Help

Diagnostic Radiation Physics Services helps nuclear medicine and radionuclide therapy programs build defensible, patient-centered release workflows. This includes patient release dose calculations, release-instruction and wallet-card templates, radiation safety procedure development, RSO program support, staff training, and inspection preparation aligned with NRC and Agreement State requirements. DRPS delivers this through its radiation safety officer consulting, radioactive material license support, and PET/CT and nuclear medicine physics services.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A patient who leaves your department warned and documented is a patient — and a program — protected.

Related Resources

References

U.S. Nuclear Regulatory Commission. Regulatory Guide 8.39, Revision 1: Release of Patients Administered Radioactive Material. 2020. nrc.gov
U.S. Nuclear Regulatory Commission. 10 CFR 35.75: Release of Individuals Containing Unsealed Byproduct Material or Implants Containing Byproduct Material. ecfr.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
Dauer LT, Williamson MJ, St Germain J, Strauss HW. Tl-201 stress tests and homeland security. J Nucl Cardiol. 2007;14(4):582-588. doi:10.1016/j.nuclcard.2007.04.021. PubMed
International Commission on Radiological Protection. ICRP Publication 94: Release of Patients after Therapy with Unsealed Radionuclides. Annals of the ICRP. 2004;34(2). icrp.org
International Atomic Energy Agency. Release of Patients After Radionuclide Therapy. IAEA Safety Reports Series No. 63. 2009. iaea.org
U.S. Nuclear Regulatory Commission. NUREG-1556, Volume 9, Revision 3: Consolidated Guidance About Materials Licenses — Program-Specific Guidance About Medical Use Licenses. nrc.gov
National Council on Radiation Protection and Measurements. NCRP Report No. 155: Management of Radionuclide Therapy Patients. 2006. ncrponline.org
International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Annals of the ICRP. 2008;38(3). icrp.org
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov